UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 691

Sortiert nach

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

Annals of oncology, 2015-03, Vol.26 (3), p.463-476

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial

Annals of oncology, 2016-04, Vol.27 (4), p.687-692

2016

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Annals of oncology, 2021-05, Vol.32 (5), p.600-608

2021

Link zum Volltext

Verfügbarkeit prüfen

Mismatch Repair Screening of Gastrointestinal Cancers: The Impact on Lynch Syndrome Detection and Immunotherapy

Journal of gastrointestinal cancer, 2023-09, Vol.54 (3), p.768-775

2023

Link zum Volltext

Verfügbarkeit prüfen

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends

Cancer treatment reviews, 2018-12, Vol.71, p.32-38

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments

OncoTargets and therapy, 2022-01, Vol.15, p.1183-1196

2022

Link zum Volltext

Verfügbarkeit prüfen

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation combined modality therapy

British journal of cancer, 2007-04, Vol.96 (8), p.1183-1190

2007

Link zum Volltext

Verfügbarkeit prüfen

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Annals of oncology, 2010-11, Vol.21 (11), p.2213-2219

2010

Link zum Volltext

Verfügbarkeit prüfen

The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital

Annals of oncology, 2019-07, Vol.30, p.iv108-iv108

2019

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of cetuximab irinotecan vs active best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

British journal of cancer, 2007-01, Vol.96 (2), p.206-212

2007

Link zum Volltext

Verfügbarkeit prüfen

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials

Annals of oncology, 2018-10, Vol.29, p.viii721-viii721

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery

Annals of oncology, 2019-07, Vol.30, p.iv55-iv55

2019

Link zum Volltext

Verfügbarkeit prüfen

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses

British journal of cancer, 2008-07, Vol.99 (1), p.6-13

2008

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study

Annals of oncology, 2019-07, Vol.30, p.iv126-iv126

2019

Link zum Volltext

Verfügbarkeit prüfen

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice

Annals of oncology, 2018-01, Vol.29 (1), p.230-236

2018

Link zum Volltext

Verfügbarkeit prüfen

Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy

Annals of oncology, 2018-10, Vol.29, p.viii214-viii214

2018

Link zum Volltext

Verfügbarkeit prüfen

Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25–39 Years Old in the UK National Health Service

Clinical oncology (Royal College of Radiologists (Great Britain)), 2021-08, Vol.33 (8), p.494-506

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii661-viii661

2018

Link zum Volltext

Verfügbarkeit prüfen

ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma

Annals of oncology, 2018-10, Vol.29, p.viii269-viii270

2018

Link zum Volltext

Verfügbarkeit prüfen

EGFR amplification (amp) and survival in the REAL-3 trial

Annals of oncology, 2018-10, Vol.29, p.viii217-viii217

2018

Link zum Volltext

Verfügbarkeit prüfen

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

European journal of cancer (1990), 2014-05, Vol.50 (8), p.1422-1429

2014

Link zum Volltext

Verfügbarkeit prüfen

Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study

ESMO open, 2024-07, Vol.9 (7), p.103622, Article 103622

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE

ESMO open, 2024-04, Vol.9 (4), p.102971-102971, Article 102971

2024

Link zum Volltext

Verfügbarkeit prüfen

Survival from cancer of the pancreas in England and Wales up to 2001

British journal of cancer, 2008-09, Vol.99 (S1), p.S24-S25

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

British journal of cancer, 2008-09, Vol.99 (6), p.868-874

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 691

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(656)
Mit Volltextzugriff
(640)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(366)
Life Sciences & Biomedicine
(271)
Humans
(255)
Biological And Medical Sciences
(151)
Female
(151)
Male
(143)
Medical Sciences
(133)
Middle Aged
(129)
Surgery
(104)
Cardiac & Cardiovascular Systems
(102)
Cardiovascular System & Cardiology
(102)
Adult
(93)
Physical Sciences
(87)
Aged
(79)
Astronomy & Astrophysics
(66)
Transplantation
(61)
Surgery . Transplantations, Organ And Tissue Grafts. Graft Diseases
(58)
Respiratory System
(47)
Cardiology. Vascular System
(43)
Heart Failure
(42)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Mismatch Repair Screening of Gastrointestinal Cancers: The Impact on Lynch Syndrome Detection and Immunotherapy

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation combined modality therapy

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital

Cost-effectiveness analysis of cetuximab irinotecan vs active best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials

Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice

Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy

Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25–39 Years Old in the UK National Health Service

Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer

ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma

EGFR amplification (amp) and survival in the REAL-3 trial

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE

Survival from cancer of the pancreas in England and Wales up to 2001

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

Suchergebnisse filtern